{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":20,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":20,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"fe933d0e8be0","filters":{"venue":"Therapeutic Advances in Hematology"}},"results":[{"id":"W2122059243","doi":"10.1177/2040620715571077","title":"Targeting polo-like kinase 1 in acute myeloid leukemia","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"PLK1; Medicine; Cytarabine; Myeloid leukemia; Leukemia; Polo-like kinase; Myeloid; Clinical trial; Oncology; Cancer research; Internal medicine; Cell cycle; Pharmacology; Cancer","authors":[{"name":"Joseph Brandwein","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05368819906423131,"gpt":0.4039952893888705,"spread":0.3503070903246392,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003952169,0.0005471819,0.001063208,0.001955281,0.0001958048,0.0006556369,0.0006965483,0.0005935172,0.003694657],"category_scores_gemma":[0.0003919551,0.0002264238,0.0004932802,0.001559862,0.0002555743,0.0009186275,0.0005939541,0.001352585,0.002088411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003696219,"about_ca_system_score_gemma":0.0005950182,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006487506,"about_ca_topic_score_gemma":0.001593948,"domain_scores_codex":[0.9998792,0.00001894203,0.00001941569,0.00001907422,0.00005081886,0.00001255294],"domain_scores_gemma":[0.9998804,0.00004412118,0.00002703898,0.000003300827,0.00003153839,0.00001347918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009190451,0.00007257298,0.0001365354,0.02106361,0.0001158434,0.0001797894,0.00005108227,0.0002762121,0.002235463,0.001982018,0.02369127,0.9501036],"study_design_scores_gemma":[0.00003761232,0.0001193926,0.0006597836,0.003441125,0.0001581684,0.00121089,0.00003930615,0.00007566602,0.0005306396,0.001164476,0.9925494,0.0000135729],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001634005,0.9987406,0.00006281251,0.000133741,0.0000991628,0.000005940747,0.00001610937,0.000005530593,0.0007727172],"genre_scores_gemma":[0.0006768238,0.9984877,0.0001043048,0.0001435938,0.0000577613,0.000005379626,0.00003362462,0.000001039595,0.0004897164],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003694657,"threshold_uncertainty_score":0.01235986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4226103605","doi":"10.1177/20406207221085202","title":"International consensus recommendations on the management of people with haemophilia B","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"Spark Therapeutics; Genentech; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Chugai Pharmaceutical; McMaster University; Pfizer","keywords":"Haemophilia; Medicine; Haemophilia B; Haemophilia A; Delphi method; Intensive care medicine; Delphi; Pediatrics","authors":[{"name":"Daniel P. Hart","is_ca":false},{"name":"Davide Matino","is_ca":true},{"name":"Jan Astermark","is_ca":false},{"name":"Gerard Dolan","is_ca":false},{"name":"Roseline d’Oiron","is_ca":false},{"name":"Cédric Hermans","is_ca":false},{"name":"Víctor Jiménez‐Yuste","is_ca":false},{"name":"Adriana Linares","is_ca":false},{"name":"Tadashi Matsushita","is_ca":false},{"name":"Simon McRae","is_ca":false},{"name":"Margareth C. Ozelo","is_ca":false},{"name":"Sean Platton","is_ca":false},{"name":"Darrel W. Stafford","is_ca":false},{"name":"Robert F. Sidonio","is_ca":false},{"name":"Andreas Tiede","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1047656392073772,"gpt":0.423291382229807,"spread":0.3185257430224298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04665945,0.00193757,0.00271449,0.009068877,0.002055495,0.004165491,0.008127568,0.01201772,0.01710948],"category_scores_gemma":[0.09724802,0.001347645,0.006160543,0.007062785,0.001955897,0.004332995,0.005997418,0.008235109,0.008996063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007426401,"about_ca_system_score_gemma":0.03778512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01622981,"about_ca_topic_score_gemma":0.01509026,"domain_scores_codex":[0.9539015,0.02248451,0.01095048,0.001428945,0.00897184,0.002262727],"domain_scores_gemma":[0.9138905,0.0284113,0.008678845,0.001508154,0.04337535,0.004135885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000105883,0.0001672756,0.00139437,0.02236138,0.0002070764,0.0007993954,0.00329889,0.001034282,0.0003207307,0.01409079,0.6086746,0.3475453],"study_design_scores_gemma":[0.0001996583,0.0001031963,0.002377917,0.08429041,0.0003396542,0.0007102179,0.002200646,0.0003203131,0.000184249,0.01098748,0.8981988,0.00008748076],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.003115261,0.2674841,0.02501356,0.5360503,0.02709767,0.007549476,0.008713168,0.000779361,0.1241971],"genre_scores_gemma":[0.04452357,0.4523273,0.2450612,0.1531819,0.005747532,0.02079367,0.0293004,0.0004306982,0.04863369],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.04665945,"threshold_uncertainty_score":0.2467617,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3094234317","doi":"10.1177/2040620720966137","title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Hematology Association; Alexion Pharmaceuticals","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Internal medicine; Immunology; Antibody; Complement system","authors":[{"name":"Hubert Schrezenmeier","is_ca":false},{"name":"Austin Kulasekararaj","is_ca":false},{"name":"Lindsay Mitchell","is_ca":false},{"name":"Flore Sicre de Fontbrune","is_ca":false},{"name":"Timothy Devos","is_ca":false},{"name":"Shinichiro Okamoto","is_ca":false},{"name":"Richard A. Wells","is_ca":true},{"name":"Scott T. Rottinghaus","is_ca":false},{"name":"Peng Liu","is_ca":false},{"name":"Stephan Ortiz","is_ca":false},{"name":"Jong Wook Lee","is_ca":false},{"name":"Gèrard Socié","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03983949947990802,"gpt":0.324679299457079,"spread":0.284839799977171,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005105282,0.001728713,0.002935296,0.0005591598,0.0005784547,0.00117099,0.0007732931,0.001788636,0.002726814],"category_scores_gemma":[0.003943751,0.0007669499,0.003200951,0.000394203,0.001034801,0.00136974,0.0005319833,0.002868203,0.0006784946],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008846485,"about_ca_system_score_gemma":0.001086737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007568944,"about_ca_topic_score_gemma":0.0009853687,"domain_scores_codex":[0.9979717,0.001070397,0.0001825133,0.0003567735,0.0001862729,0.0002323551],"domain_scores_gemma":[0.9963122,0.000964828,0.001094383,0.0005088598,0.0003069925,0.0008127572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9589591,0.01706201,0.003860617,0.0002084915,0.001353027,0.0000619125,0.00009939599,0.0002659772,0.002627085,0.00003713611,0.0003278818,0.01513724],"study_design_scores_gemma":[0.7361608,0.2456381,0.0149158,0.00003013589,0.001147578,0.00009370266,0.00003105303,0.000552933,0.0008239978,0.00007979167,0.0004954144,0.00003062888],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964857,0.001291005,0.0002955196,0.0001314152,0.00009938357,0.0009403743,0.0003533447,0.00003767235,0.000365576],"genre_scores_gemma":[0.995487,0.0006776845,0.0006729692,0.0003168065,0.0002828472,0.001212895,0.0007411264,0.000009646781,0.0005990212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005105282,"threshold_uncertainty_score":0.02699965,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285185611","doi":"10.1177/20406207221091046","title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":31,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"AstraZeneca","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Complement system; Complement component 5; Immunology; CD59; Complement (music); Internal medicine; Antibody","authors":[{"name":"Austin Kulasekararaj","is_ca":false},{"name":"Robert A. Brodsky","is_ca":false},{"name":"Jun‐ichi Nishimura","is_ca":false},{"name":"Christopher J. Patriquin","is_ca":true},{"name":"Hubert Schrezenmeier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05434598404694474,"gpt":0.3689961274477568,"spread":0.3146501434008121,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005842786,0.0002416101,0.0003162011,0.0002970936,0.0002255655,0.000485488,0.0002667758,0.0005440271,0.0007425394],"category_scores_gemma":[0.001689202,0.00005859769,0.0002639727,0.0001813276,0.0004177152,0.0003206579,0.0002506394,0.0009352682,0.0001391188],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005699674,"about_ca_system_score_gemma":0.000558951,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002264475,"about_ca_topic_score_gemma":0.001695334,"domain_scores_codex":[0.9996749,0.0001135542,0.00003027563,0.00003877426,0.00009079653,0.00005171674],"domain_scores_gemma":[0.9995313,0.0001578469,0.0001232961,0.00002201501,0.00008869097,0.00007696146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004523791,0.0004923285,0.1305631,0.002729628,0.0008792833,0.01940254,0.000676944,0.001653162,0.08846147,0.01858202,0.02927319,0.7027626],"study_design_scores_gemma":[0.0007771079,0.003496992,0.4379891,0.003062558,0.001458377,0.137261,0.0009213017,0.009235154,0.06324431,0.03465128,0.3076954,0.0002074392],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4572605,0.4893816,0.008445439,0.01570861,0.001831098,0.00008621082,0.0004197349,0.0001797432,0.02668704],"genre_scores_gemma":[0.9595369,0.03451334,0.001524933,0.002198782,0.0007825533,0.00002446997,0.0001782514,0.00001232537,0.001228454],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002264475,"threshold_uncertainty_score":0.004502654,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3094556560","doi":"10.1177/2040620720966888","title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Pfizer","keywords":"Medicine; Haemophilia; Dosing; Clotting factor; Haemophilia A; Intensive care medicine; Trough level; Population; Pharmacokinetics; Surgery; Internal medicine","authors":[{"name":"Cédric Hermans","is_ca":false},{"name":"G. Dolan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1926136747927358,"gpt":0.5560222201151694,"spread":0.3634085453224336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002314352,0.001277552,0.002487857,0.003019817,0.0003201261,0.001988345,0.00173178,0.002122876,0.003408596],"category_scores_gemma":[0.004378531,0.0006019595,0.001432696,0.002728459,0.001027639,0.002440074,0.001048697,0.00247982,0.001950617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001254783,"about_ca_system_score_gemma":0.002327431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002180395,"about_ca_topic_score_gemma":0.001938887,"domain_scores_codex":[0.9991084,0.0002834457,0.0001774936,0.0001237394,0.0002667497,0.00004011296],"domain_scores_gemma":[0.9969606,0.002155041,0.0003044421,0.00006032839,0.0004450099,0.00007462844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001154901,0.0001363761,0.0004588059,0.04815084,0.000203835,0.0003726802,0.0001663029,0.001518206,0.0005208828,0.008674914,0.03064739,0.9090344],"study_design_scores_gemma":[0.00003481981,0.0002924678,0.001897436,0.03735089,0.000465281,0.00255133,0.0001869093,0.0008064021,0.000315351,0.008144272,0.9478829,0.00007195168],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000611538,0.998628,0.0002883421,0.0004657601,0.000130857,0.00001040395,0.0000164824,0.000005850741,0.0003931774],"genre_scores_gemma":[0.0005701442,0.9983376,0.0004594689,0.0002275496,0.0002421546,0.00001357253,0.0000203499,0.000001903191,0.0001271807],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003408596,"threshold_uncertainty_score":0.01223963,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4402541521","doi":"10.1177/20406207241275376","title":"Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ipsen; GlaxoSmithKline","keywords":"Medicine; Myeloid; Internal medicine; Oncology","authors":[{"name":"Justin M. Watts","is_ca":false},{"name":"Mark D. Minden","is_ca":true},{"name":"Kimo Bachiashvili","is_ca":false},{"name":"Andrew M. Brunner","is_ca":false},{"name":"Sameem Abedin","is_ca":false},{"name":"Timothy Crossman","is_ca":false},{"name":"Magdalena Zając","is_ca":false},{"name":"V. V. Moroz","is_ca":false},{"name":"Jacqueline L. Egger","is_ca":false},{"name":"Aarti Tarkar","is_ca":false},{"name":"Brandon E. Kremer","is_ca":false},{"name":"Olena Barbash","is_ca":false},{"name":"Gautam Borthakur","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01123824306989505,"gpt":0.329394950144116,"spread":0.3181567070742209,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332078,0.001117837,0.001211175,0.0002862531,0.0003208221,0.0004879455,0.000467537,0.000546732,0.003264112],"category_scores_gemma":[0.0007953027,0.0004008664,0.0005673071,0.0003323,0.0005954485,0.0005129185,0.0003032627,0.001816345,0.0007646875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005951319,"about_ca_system_score_gemma":0.001303915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004481628,"about_ca_topic_score_gemma":0.001348218,"domain_scores_codex":[0.9996973,0.0001333175,0.00002453375,0.00004970883,0.00003807021,0.00005707396],"domain_scores_gemma":[0.9994036,0.00008704773,0.0001722707,0.00004299159,0.00004069303,0.0002533278],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5853171,0.09535779,0.03971266,0.001210805,0.001223347,0.001074784,0.0006265301,0.003896294,0.1226985,0.0005040028,0.007597974,0.1407801],"study_design_scores_gemma":[0.3790042,0.5663359,0.04035295,0.00004664864,0.0003544933,0.0009626171,0.0001179064,0.001457287,0.0074508,0.0001989618,0.003685314,0.00003292883],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994916,0.001138274,0.000408196,0.0001956686,0.00003188718,0.001814777,0.0006748437,0.00004829155,0.0007720372],"genre_scores_gemma":[0.9931588,0.0009343757,0.001279643,0.0004184625,0.0000820127,0.001577015,0.001535482,0.00001178638,0.001002468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003264112,"threshold_uncertainty_score":0.01091951,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160410546","doi":"10.1177/2040620712471553","title":"The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Anaplastic lymphoma kinase; Cancer research; Carcinogenesis; Anaplastic large-cell lymphoma; Tyrosine kinase; STAT protein; Signal transduction; STAT3; Biology; Medicine; Lymphoma; Cell biology; Cancer; Pathology; Immunology; Internal medicine; Lung cancer","authors":[{"name":"Raymond Lai","is_ca":true},{"name":"Robert J. Ingham","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01015474149840613,"gpt":0.2801749200807791,"spread":0.270020178582373,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004522307,0.0010185,0.001191407,0.002836123,0.0002805237,0.001197245,0.0007449939,0.001495492,0.002984585],"category_scores_gemma":[0.0006712948,0.0003350593,0.0005962503,0.001679859,0.0005147905,0.002274767,0.0006446753,0.002149197,0.001697481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006492727,"about_ca_system_score_gemma":0.0007867695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007154383,"about_ca_topic_score_gemma":0.001043741,"domain_scores_codex":[0.9998473,0.00002411323,0.0000350203,0.00003664912,0.00003835345,0.00001848572],"domain_scores_gemma":[0.9995657,0.0001845889,0.00007434589,0.00001290645,0.0001105742,0.00005192269],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003234736,0.0001893832,0.00153804,0.0163119,0.0001699019,0.003198909,0.0001789815,0.0006278622,0.009091503,0.004857438,0.1014479,0.8620647],"study_design_scores_gemma":[0.00001355155,0.0001790724,0.001590997,0.001787613,0.0001851095,0.01087833,0.0001083817,0.0002078091,0.001024292,0.001755409,0.9822304,0.00003900326],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007013381,0.9941524,0.0005208468,0.001235033,0.002047353,0.000006600542,0.00005389011,0.00002335621,0.001259252],"genre_scores_gemma":[0.002177261,0.9887403,0.0006640455,0.001122213,0.006119989,0.00001154236,0.0001439828,0.000005552772,0.001015102],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002984585,"threshold_uncertainty_score":0.009984434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3112714545","doi":"10.1177/2040620720977039","title":"Adverse events in second- and third-line treatments for acute and chronic graft- <i>versus</i> -host disease: systematic review","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Extracorporeal Photopheresis; Graft-versus-host disease; Adverse effect; Internal medicine; Incidence (geometry); Hematopoietic stem cell transplantation; Population; Disease; Immunology","authors":[{"name":"Vladica Veličković","is_ca":false},{"name":"Emily McIlwaine","is_ca":false},{"name":"Rongrong Zhang","is_ca":false},{"name":"Tim Spelman","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0370342065950142,"gpt":0.3841141538634325,"spread":0.3470799472684183,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005555012,0.001013549,0.005434199,0.005861455,0.000384424,0.001654387,0.001107501,0.001278293,0.002922834],"category_scores_gemma":[0.03036871,0.0006018792,0.007461721,0.005409729,0.0006121919,0.001229803,0.000906834,0.0009011255,0.0001951744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001990762,"about_ca_system_score_gemma":0.004682085,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004590831,"about_ca_topic_score_gemma":0.01176384,"domain_scores_codex":[0.9929404,0.002325909,0.002941996,0.000471277,0.001161651,0.0001587007],"domain_scores_gemma":[0.9656681,0.02298741,0.008718136,0.0003623663,0.002019187,0.0002448805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003096083,0.00001519287,0.001639667,0.9537213,0.01336221,0.00008398278,0.0001121662,0.0001029579,0.0001220442,0.0001258007,0.001259101,0.02914592],"study_design_scores_gemma":[0.0005422814,0.0004878709,0.01288388,0.8444077,0.1196981,0.0008435645,0.000258939,0.0001331868,0.0002833929,0.0003141218,0.02009891,0.00004813901],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001472947,0.9974806,0.00009108462,0.00013716,0.00007016036,0.000150691,0.00036524,0.000005440921,0.0002267566],"genre_scores_gemma":[0.03603943,0.9618286,0.0005246447,0.000620621,0.0001024434,0.0004107343,0.0003536939,0.000005990585,0.0001137364],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005861455,"threshold_uncertainty_score":0.02937812,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2756236937","doi":"10.1177/2040620717729128","title":"Red cell genotyping precision medicine: a conference summary","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Blood groups and transfusion","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Héma-Québec","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; Grifols; Australian Government; Canadian Blood Services","keywords":"Genotyping; Precision medicine; Medicine; Clinical Practice; Medical physics; Family medicine; Pathology; Genotype; Genetics; Biology","authors":[{"name":"Gregory A. Denomme","is_ca":false},{"name":"Waseem Q. Anani","is_ca":false},{"name":"Neil D. Avent","is_ca":false},{"name":"Gregor Bein","is_ca":false},{"name":"Lynne Briggs","is_ca":false},{"name":"Razvan Lapadat","is_ca":false},{"name":"Celina Montemayor","is_ca":false},{"name":"María Rios","is_ca":false},{"name":"Maryse St‐Louis","is_ca":true},{"name":"Lynne Uhl","is_ca":false},{"name":"Silvano Wendel","is_ca":false},{"name":"Willy A. Flegel","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1255519246318827,"gpt":0.4248344417129931,"spread":0.2992825170811104,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00247672,0.001103327,0.001078272,0.003574532,0.0005380359,0.002094196,0.001087849,0.002173042,0.008093217],"category_scores_gemma":[0.003788481,0.0004018667,0.0008392603,0.003243621,0.0004916766,0.002798738,0.001481554,0.003505755,0.004892616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00123557,"about_ca_system_score_gemma":0.003499537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001198409,"about_ca_topic_score_gemma":0.001923966,"domain_scores_codex":[0.9991422,0.000161883,0.0001606624,0.0001100061,0.0003555762,0.00006971763],"domain_scores_gemma":[0.998083,0.0006617734,0.0001952022,0.00004201619,0.0008500476,0.0001680187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006408828,0.00006132973,0.0001758319,0.02000163,0.00007807234,0.000436337,0.0001563977,0.000280742,0.0009689264,0.00650615,0.2742386,0.6970319],"study_design_scores_gemma":[0.00000532468,0.00002659572,0.0001879825,0.005011997,0.000035802,0.0005932708,0.00004250324,0.00002488784,0.0001518515,0.0007683765,0.9931383,0.00001316914],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001135118,0.9839935,0.0003689064,0.005911394,0.006112475,0.0000315975,0.00008128113,0.0000269277,0.003360355],"genre_scores_gemma":[0.0005909116,0.9906111,0.0004616438,0.002879066,0.003258056,0.0000291547,0.0001419912,0.000007323387,0.002020722],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008093217,"threshold_uncertainty_score":0.02707446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168385579","doi":"10.1177/2040620715586528","title":"Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective","year":2015,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Foothills Medical Centre; University of Calgary","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Fludarabine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Chemotherapy; Cyclophosphamide; Leukemia; Venetoclax; Immunology; Lymphoma","authors":[{"name":"Carolyn Owen","is_ca":true},{"name":"Douglas A. Stewart","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06151108374895914,"gpt":0.4038393252012171,"spread":0.3423282414522579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006365445,0.0006732229,0.00114761,0.002284883,0.0002132264,0.0006918118,0.0007929704,0.0009135855,0.002191911],"category_scores_gemma":[0.0006690632,0.0002344503,0.0006206786,0.00156754,0.0003335423,0.0009033835,0.0004613272,0.001696297,0.0009991113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005184734,"about_ca_system_score_gemma":0.0007351594,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009386099,"about_ca_topic_score_gemma":0.002149395,"domain_scores_codex":[0.999827,0.00003585839,0.00002996115,0.00003028006,0.00005878598,0.00001823084],"domain_scores_gemma":[0.9996828,0.0001525009,0.00005194809,0.000005894239,0.00007694112,0.00002992297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001247565,0.00007771664,0.0002136249,0.01732921,0.00013958,0.0002011795,0.00005859081,0.0002773498,0.001006078,0.001745111,0.02202547,0.9568013],"study_design_scores_gemma":[0.00007026518,0.0002513391,0.001437342,0.009899175,0.0003402928,0.002815424,0.00007627693,0.0001565349,0.0004595777,0.001861803,0.9826057,0.00002633432],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00008678668,0.9992965,0.00004167479,0.0001771578,0.00007481458,0.000002255725,0.000007141618,0.00000327191,0.0003102315],"genre_scores_gemma":[0.0005006581,0.9989966,0.0000913268,0.0001453096,0.0000974363,0.000003479183,0.00001615426,7.353742e-7,0.0001484674],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002284883,"threshold_uncertainty_score":0.007332623,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102216347","doi":"10.1177/2040620712453067","title":"Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton Health Sciences; Hamilton General Hospital","funders":"Bayer HealthCare","keywords":"Medicine; Rivaroxaban; Dabigatran; Apixaban; Edoxaban; Deep vein; Pulmonary embolism; Atrial fibrillation; Thrombosis; Intensive care medicine; Warfarin; Surgery; Internal medicine","authors":[{"name":"Alexander G.G. Turpie","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03052497582906794,"gpt":0.3507486128392116,"spread":0.3202236370101437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005622409,0.000505565,0.0007037763,0.0009163626,0.0003929924,0.001851789,0.0005810632,0.001504541,0.004755917],"category_scores_gemma":[0.006799635,0.0001560416,0.00039803,0.001078627,0.001024371,0.002351367,0.00079124,0.003212,0.001782062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009338394,"about_ca_system_score_gemma":0.001755758,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001238065,"about_ca_topic_score_gemma":0.001342655,"domain_scores_codex":[0.9979199,0.0008424639,0.0002333618,0.0001623843,0.0007743508,0.00006753698],"domain_scores_gemma":[0.9961587,0.001678667,0.0004224157,0.0002308864,0.001249145,0.000260251],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003274487,0.0002752946,0.00140742,0.001740579,0.00007355979,0.0001798281,0.0001053574,0.0003270966,0.001652522,0.01286807,0.03229204,0.9487508],"study_design_scores_gemma":[0.0002211152,0.0007082883,0.006551952,0.002619716,0.0002253194,0.002358623,0.0001690322,0.0007781503,0.002206486,0.01910545,0.9650105,0.0000453159],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003096996,0.9338341,0.002613636,0.0487616,0.002517031,0.00001922567,0.00005609235,0.00003105952,0.009070251],"genre_scores_gemma":[0.03474997,0.9351791,0.004897817,0.01041732,0.01170786,0.00002627858,0.00006672685,0.00002054274,0.002934407],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005622409,"threshold_uncertainty_score":0.02973443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3034142645","doi":"10.1177/2040620720914490","title":"PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Context (archaeology); Oncology; Hodgkin lymphoma; Interim; Regimen; Lymphoma; Internal medicine; Radiation therapy; Clinical trial; Toxicity; Stage (stratigraphy); Medical physics","authors":[{"name":"Noémie Lang","is_ca":true},{"name":"Michael Crump","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1572027979134116,"gpt":0.369600646188655,"spread":0.2123978482752434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005706743,0.0006429456,0.001340435,0.002028046,0.0001874708,0.0006695945,0.0006535025,0.0005222652,0.004296835],"category_scores_gemma":[0.0008533111,0.0001714971,0.0008172655,0.001735583,0.0002824172,0.0006990766,0.0004855234,0.001209727,0.001231825],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000426772,"about_ca_system_score_gemma":0.0007400058,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008225693,"about_ca_topic_score_gemma":0.002139587,"domain_scores_codex":[0.9998123,0.000048955,0.00003642532,0.00003309663,0.00005425758,0.00001501038],"domain_scores_gemma":[0.9996954,0.0001875262,0.00004721379,0.000008984652,0.00004633708,0.00001452158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001108817,0.00006887438,0.00009848539,0.04453124,0.0002216454,0.0000965144,0.0000433591,0.000270155,0.001036154,0.00126516,0.01004077,0.9422168],"study_design_scores_gemma":[0.00009248699,0.0003476524,0.001971229,0.02470401,0.0009340392,0.001894729,0.0001014646,0.0001438593,0.000763682,0.001677201,0.967344,0.00002570013],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001026092,0.9991991,0.00005733507,0.00008215972,0.00006317996,0.000007419112,0.00001411748,0.000003841265,0.0004702962],"genre_scores_gemma":[0.0006416162,0.9989085,0.0001292717,0.0001109855,0.00003574069,0.000006735012,0.00002414004,8.23516e-7,0.0001421512],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004296835,"threshold_uncertainty_score":0.01437438,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386205570","doi":"10.1177/20406207231195594","title":"Luspatercept for transfusion-dependent β-thalassemia: time to get real","year":2023,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"bluebird bio; Ionis Pharmaceuticals; La Jolla Pharmaceutical Company; Alexion Pharmaceuticals; Vertex Pharmaceuticals; Celgene; Sanofi; Amgen; Vifor Pharma; Pfizer; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Medicine; Thalassemia; Blood transfusion; Intensive care medicine; Internal medicine","authors":[{"name":"Khaled M. Musallam","is_ca":false},{"name":"Sujit Sheth","is_ca":false},{"name":"Maria Domenica Cappellini","is_ca":false},{"name":"Antonis Kattamis","is_ca":false},{"name":"Kevin H.M. Kuo","is_ca":true},{"name":"Alì Taher","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009589591266610426,"gpt":0.3126826305464226,"spread":0.3030930392798122,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00733665,0.002940694,0.004388656,0.002117379,0.002086326,0.006227218,0.003275412,0.01567411,0.008129175],"category_scores_gemma":[0.01713873,0.0009990562,0.002807457,0.001251639,0.001773774,0.003991899,0.001085836,0.02217706,0.006557521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002828178,"about_ca_system_score_gemma":0.002380784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001519405,"about_ca_topic_score_gemma":0.004387926,"domain_scores_codex":[0.9961527,0.0007980323,0.000528877,0.0003494482,0.00190083,0.0002700082],"domain_scores_gemma":[0.9862299,0.006673262,0.0008879911,0.0003010484,0.003767051,0.002140731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009453321,0.00002278157,0.00002136148,0.000408754,0.000042327,0.000140093,0.000008844951,0.00002995286,0.00007637346,0.0002789826,0.9881841,0.01069198],"study_design_scores_gemma":[0.0003102478,0.0001143448,0.0003760659,0.00093544,0.0002029153,0.0005054648,0.00003761429,0.0002976042,0.0001711385,0.001243513,0.9957709,0.00003468669],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00004679754,0.01863871,0.0001507156,0.03341214,0.9461355,0.00001999649,0.00003821121,0.0000533441,0.001504435],"genre_scores_gemma":[0.0004278971,0.01046943,0.0001250727,0.0292368,0.9548283,0.00002067388,0.00002609633,0.0000257088,0.004840052],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.01567411,"threshold_uncertainty_score":0.03880036,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4295903721","doi":"10.1177/20406207221118429","title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10 <sup>9</sup> /L to &lt;100 × 10 <sup>9</sup> /L) at baseline: the final analysis of EXPAND","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Genentech; AOP Orphan; Sierra Oncology; CTI Biopharma; Incyte; FibroGen; Gilead Sciences; BeiGene; Sanofi; MorphoSys; Celgene; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Adverse effect; Internal medicine; Clinical endpoint; Anemia; Phases of clinical research; Gastroenterology; Discontinuation; International Prognostic Scoring System; Clinical trial; Bone marrow; Myelodysplastic syndromes","authors":[{"name":"Paola Guglielmelli","is_ca":false},{"name":"Jean‐Jacques Kiladjian","is_ca":false},{"name":"Alessandro M. Vannucchi","is_ca":false},{"name":"Minghui Duan","is_ca":false},{"name":"Haitao Meng","is_ca":false},{"name":"Ling Pan","is_ca":false},{"name":"Guangsheng He","is_ca":false},{"name":"Srđan Verstovšek","is_ca":false},{"name":"Françoise Boyer","is_ca":false},{"name":"Fiorenza Barraco","is_ca":false},{"name":"Dietger Niederwieser","is_ca":false},{"name":"Ester Pungolino","is_ca":false},{"name":"Anna Marina Liberati","is_ca":false},{"name":"Claire Harrison","is_ca":false},{"name":"Pantelia Roussou","is_ca":false},{"name":"Monika Wroclawska","is_ca":false},{"name":"Divyadeep Karumanchi","is_ca":false},{"name":"Karen Sinclair","is_ca":false},{"name":"Peter A.W. te Boekhorst","is_ca":false},{"name":"Heinz Gisslinger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01325738480847344,"gpt":0.2773913357063457,"spread":0.2641339508978723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001412846,0.0005045759,0.0009711421,0.0002672368,0.0002162962,0.0004278398,0.0002914198,0.0003858508,0.001283565],"category_scores_gemma":[0.0009791203,0.0002101386,0.0007279966,0.0002068309,0.0002775638,0.0004866741,0.0003222567,0.0007461471,0.0002463019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005155226,"about_ca_system_score_gemma":0.0006405453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003439388,"about_ca_topic_score_gemma":0.001381248,"domain_scores_codex":[0.9995989,0.0001817027,0.00003122379,0.00006818875,0.00006404573,0.00005599135],"domain_scores_gemma":[0.9994349,0.0001562053,0.0001712523,0.00003944802,0.00004334998,0.0001548551],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5271119,0.01004758,0.2407935,0.0006174427,0.002205919,0.0008621794,0.0004290433,0.003162978,0.04242361,0.0003074242,0.004346212,0.1676922],"study_design_scores_gemma":[0.1257861,0.2284953,0.6187454,0.0001323827,0.002445921,0.002160957,0.0001820584,0.00535481,0.01070088,0.000396615,0.005512275,0.00008729869],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980926,0.0006765554,0.0001057911,0.0000746733,0.000004684226,0.000152276,0.0003066148,0.00001219549,0.0005747145],"genre_scores_gemma":[0.9977399,0.000246605,0.0003423809,0.0001406031,0.00002295657,0.0001725341,0.001075462,0.000003096505,0.0002564929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001412846,"threshold_uncertainty_score":0.007471979,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391890091","doi":"10.1177/20406207231218624","title":"The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"Takeda Pharmaceuticals International; Grifols; Swedish Orphan Biovitrum; Baxalta; CSL Behring; Biogen; Novo Nordisk; Sanofi; Pfizer","keywords":"Medicine; Observational study; Interim analysis; Clinical endpoint; Adverse effect; Quality of life (healthcare); Internal medicine; Clinical trial; Pediatrics; Physical therapy","authors":[{"name":"Margareth C. Ozelo","is_ca":false},{"name":"Cédric Hermans","is_ca":false},{"name":"Manuel Carção","is_ca":true},{"name":"Benoît Guillet","is_ca":false},{"name":"Joan Gu","is_ca":false},{"name":"Randy Guerra","is_ca":false},{"name":"Leilei Tang","is_ca":false},{"name":"Kate Khair","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01639607912888928,"gpt":0.3499241047546473,"spread":0.333528025625758,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004384999,0.000332442,0.0008910359,0.0008323634,0.0005772342,0.00111061,0.000363355,0.0007622017,0.001046483],"category_scores_gemma":[0.005450063,0.0001683041,0.001412371,0.0008764518,0.0003172785,0.001056163,0.0007242427,0.0009867733,0.0003564617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005391231,"about_ca_system_score_gemma":0.0005469618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001638426,"about_ca_topic_score_gemma":0.001549722,"domain_scores_codex":[0.9984523,0.0005926127,0.0001957796,0.0001983906,0.0003665403,0.0001943209],"domain_scores_gemma":[0.9919258,0.001391152,0.004238638,0.0005676365,0.0009472365,0.0009295371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0137192,0.0009176068,0.9728059,0.0000732148,0.0006830565,0.0001094769,0.000135016,0.0002598918,0.0002541136,0.00003424758,0.0005097502,0.01049859],"study_design_scores_gemma":[0.0005682855,0.006331509,0.9906707,0.00002562828,0.0006266547,0.000178209,0.0001409451,0.0004139528,0.0002058121,0.00004031268,0.0007746193,0.00002346071],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967899,0.001041979,0.00009917073,0.0001081976,0.00001531232,0.00005751738,0.001154403,0.000004962245,0.0007284742],"genre_scores_gemma":[0.9965738,0.0003241419,0.0001057415,0.0000893875,0.00003901485,0.00005215996,0.002578735,0.000002558304,0.0002346689],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004384999,"threshold_uncertainty_score":0.02319032,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4381855175","doi":"10.1177/20406207231177282","title":"Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Sierra Oncology; National Cancer Institute; Galecto; Incyte; Servier; Celgene","keywords":"Medicine; Myelofibrosis; Essential thrombocythemia; Polycythemia vera; Bone marrow; Internal medicine; Myeloid leukemia; Myeloproliferative neoplasm; Oncology; Population; Myeloid; Acute leukemia; Haematopoiesis; Leukemia; Immunology; Stem cell","authors":[{"name":"Helen Ajufo","is_ca":false},{"name":"Julian A. Waksal","is_ca":false},{"name":"John Mascarenhas","is_ca":false},{"name":"Raajit K. Rampal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.170944473417937,"gpt":0.4451018780176871,"spread":0.2741574045997501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005574322,0.0005790264,0.001049579,0.001409803,0.0002431612,0.0008204663,0.0007408589,0.0008490498,0.003139611],"category_scores_gemma":[0.0009464262,0.0001573705,0.0004982425,0.001198841,0.0003126543,0.001122789,0.0005383831,0.00175568,0.00133726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000465872,"about_ca_system_score_gemma":0.0008250952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007034943,"about_ca_topic_score_gemma":0.00161701,"domain_scores_codex":[0.9998077,0.00003943971,0.00003315391,0.000032206,0.00006722671,0.0000204103],"domain_scores_gemma":[0.9995597,0.0002161636,0.00005375881,0.00001101041,0.0001256476,0.00003372566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006374186,0.00007778359,0.0001402146,0.0117338,0.00006180671,0.000122523,0.00004403957,0.0002944455,0.0008167474,0.001740404,0.02855666,0.9563478],"study_design_scores_gemma":[0.00002673129,0.0001729196,0.000771167,0.006538318,0.0001754102,0.00141328,0.00007077986,0.0001588268,0.0003578175,0.001741563,0.988556,0.00001709998],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001364085,0.9983678,0.0000930952,0.000525108,0.0002017281,0.000003507711,0.00001682802,0.000008859377,0.0006466619],"genre_scores_gemma":[0.0006338835,0.9983784,0.0001500332,0.0003209885,0.000211695,0.000004666356,0.00003022786,0.000001817366,0.0002683115],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003139611,"threshold_uncertainty_score":0.01050305,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405416708","doi":"10.1177/20406207241298088","title":"Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Agios Pharmaceuticals; Vertex Pharmaceuticals; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Blood transfusion; Thalassemia; Internal medicine; Retrospective cohort study; Demographics; Anemia; Hemoglobin; Medical record; Pediatrics; Gastroenterology; Surgery; Demography","authors":[{"name":"Maria Domenica Cappellini","is_ca":false},{"name":"Mrudula B. Glassberg","is_ca":false},{"name":"Juliana Meyers","is_ca":false},{"name":"Maria Jimenez","is_ca":false},{"name":"Tram Nham","is_ca":false},{"name":"Luciana Bueno","is_ca":false},{"name":"Jan Sieluk","is_ca":false},{"name":"Aylin Yücel","is_ca":false},{"name":"Ferras Alashkar","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01450649536129391,"gpt":0.3364064701540063,"spread":0.3218999747927124,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001199778,0.0001876991,0.0004163492,0.001850073,0.000517941,0.0006879233,0.0003864274,0.0003976416,0.001404067],"category_scores_gemma":[0.004272036,0.0003552858,0.0003949851,0.002780585,0.0003740829,0.001083008,0.0005559659,0.0005444717,0.0003114767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007363661,"about_ca_system_score_gemma":0.0006575597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005829964,"about_ca_topic_score_gemma":0.00602206,"domain_scores_codex":[0.9987025,0.0003010782,0.0003524005,0.0002406493,0.0002548666,0.0001484227],"domain_scores_gemma":[0.9950235,0.0009342277,0.002877311,0.0002996231,0.0004977228,0.0003676778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00002792887,0.00001990595,0.9993513,0.000007781748,0.00001036078,0.0000508975,0.00009198213,0.000009836583,0.00003382359,0.000004506996,0.0000590957,0.0003326443],"study_design_scores_gemma":[0.000008044394,0.0001214375,0.9980988,0.00001446361,0.00001743948,0.0006508451,0.0006341751,0.0001269563,0.0000570634,0.000008284536,0.000257067,0.000005349929],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980749,0.0001759041,0.00007991545,0.00003955581,0.000002345618,0.00003662626,0.001320068,0.00000460551,0.000266084],"genre_scores_gemma":[0.9983772,0.0001278474,0.0001514474,0.00004529263,0.000006525869,0.00004322488,0.001181942,0.000002112804,0.00006435196],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005829964,"threshold_uncertainty_score":0.01159203,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4412014975","doi":"10.1177/20406207251342199","title":"Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AOP Orphan; Swedish Orphan Biovitrum; Novartis Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Celgene; Alexion Pharmaceuticals; Ariad Pharmaceuticals; Gilead Sciences; RWTH Aachen University; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Ruxolitinib; Phlebotomy; Internal medicine; Polycythemia vera; Thrombosis; Hematology; Retrospective cohort study; Myelofibrosis; Gastroenterology; Surgery; Bone marrow","authors":[{"name":"Steffen Koschmieder","is_ca":false},{"name":"Clemens Schulte","is_ca":false},{"name":"Eyck von der Heyde","is_ca":false},{"name":"Lambert Busque","is_ca":true},{"name":"Françoise Boyer‐Perrard","is_ca":false},{"name":"Timothy Devos","is_ca":false},{"name":"Francesco Passamonti","is_ca":false},{"name":"Wendy Y. Cheng","is_ca":false},{"name":"Mu Cheng","is_ca":false},{"name":"Marja Nuortti","is_ca":false},{"name":"Volker Baum","is_ca":false},{"name":"Claire Harrison","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02571890817822953,"gpt":0.3605291126465878,"spread":0.3348102044683583,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008432664,0.0002571788,0.0005356873,0.0003596435,0.0002695532,0.0006035198,0.0002607025,0.0004749948,0.0006984656],"category_scores_gemma":[0.00129711,0.0001457198,0.0005486615,0.0004168043,0.0002726712,0.0004574727,0.0003025704,0.0004412531,0.0001441752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004124539,"about_ca_system_score_gemma":0.0002027746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005391995,"about_ca_topic_score_gemma":0.0007696262,"domain_scores_codex":[0.999624,0.0001256405,0.00003693888,0.0001002391,0.0000581118,0.00005504943],"domain_scores_gemma":[0.998724,0.0002357056,0.0005399209,0.0000815945,0.00007624668,0.0003425243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005975617,0.0004007248,0.9867582,0.00002520882,0.0003204645,0.0001842753,0.00008669668,0.0001517721,0.0008766043,0.00001814968,0.0001743421,0.00502805],"study_design_scores_gemma":[0.0008687628,0.004234989,0.9929512,0.00001032903,0.0002159354,0.0006127273,0.0001150446,0.0004840882,0.0002543383,0.00003672038,0.0002045481,0.00001134517],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9996918,0.0001185675,0.00001919714,0.00001087932,0.000002810528,0.000007312564,0.00006270497,9.547842e-7,0.00008572861],"genre_scores_gemma":[0.999608,0.00004509811,0.0000218043,0.00002401945,0.00001032816,0.000006327345,0.0002482623,4.877058e-7,0.00003576524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008432664,"threshold_uncertainty_score":0.004459679,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4415458924","doi":"10.1177/20406207251388051","title":"Immunoglobulin treatment and clinical outcomes: data from the Ontario Immunoglobulin Treatment program multicenter case registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; University of Ottawa; Sault Area Hospital; Public Health Ontario; University of Toronto; Ottawa Hospital","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Antibody; Clinical trial; Antibody therapy; Health care; Multicenter study; Healthcare system; MEDLINE","authors":[{"name":"Sarah Shehadeh","is_ca":true},{"name":"Stephen Betschel","is_ca":true},{"name":"D. William Cameron","is_ca":true},{"name":"Danny Hill","is_ca":true},{"name":"Susan Waserman","is_ca":true},{"name":"Juthaporn Cowan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06523791734071023,"gpt":0.4231188872636341,"spread":0.3578809699229239,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00186857,0.0002431756,0.0004511506,0.002338351,0.001013835,0.0008983048,0.001146386,0.0003573944,0.001589929],"category_scores_gemma":[0.007053893,0.0003041339,0.0003847684,0.007391617,0.0005389081,0.0005260605,0.0009261147,0.0003494741,0.0003108416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008710359,"about_ca_system_score_gemma":0.01138623,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.7150772,"about_ca_topic_score_gemma":0.7846403,"domain_scores_codex":[0.9968848,0.000355637,0.0003827905,0.0003831422,0.001422652,0.0005710027],"domain_scores_gemma":[0.9906434,0.0006843826,0.005225508,0.000566792,0.002047127,0.0008327002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005521482,0.00001506333,0.9970673,0.00002280983,0.00002414843,0.00006445504,0.0001526985,0.00002846699,0.00004566208,0.00002122014,0.001186514,0.001316441],"study_design_scores_gemma":[0.00001140949,0.00001487378,0.9989808,0.00001675963,0.00001595935,0.00008313557,0.000170433,0.00007254907,0.00001757904,0.000006536107,0.0006063818,0.000003547004],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751832,0.0005634752,0.0001945223,0.0002465027,0.000006083292,0.0002111882,0.02061312,0.00002119761,0.002960739],"genre_scores_gemma":[0.9823714,0.0005747653,0.0003045019,0.00009603506,0.00001380603,0.0002140078,0.01605259,0.000008966041,0.0003637997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7150772,"threshold_uncertainty_score":0.5732016,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7116052349","doi":"10.1177/20406207251401313","title":"The efficacy and safety of anti-CD20 antibody for the treatment of B-ALL: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Hematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Meta-analysis; Clinical trial; Adverse effect; Antibody; Systematic review; Randomized controlled trial; MEDLINE","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.04353487925067105,"gpt":0.4129634762267176,"spread":0.3694285969760466,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01547456,0.003333082,0.02226855,0.00951589,0.0007088464,0.003527007,0.002226169,0.002339703,0.003157533],"category_scores_gemma":[0.02865552,0.001689853,0.04612382,0.009170073,0.0007928496,0.002129069,0.001710991,0.001955997,0.000320849],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00327851,"about_ca_system_score_gemma":0.004473238,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00612728,"about_ca_topic_score_gemma":0.01282825,"domain_scores_codex":[0.9892777,0.004843209,0.003275806,0.0009316577,0.00136321,0.0003085064],"domain_scores_gemma":[0.9842018,0.01134789,0.00238285,0.0004935957,0.001369561,0.0002042525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001306859,0.00002458255,0.001748823,0.4444303,0.5401629,0.0001117079,0.00007417477,0.0005301677,0.0002324666,0.0001351604,0.0004626223,0.01078038],"study_design_scores_gemma":[0.0003459545,0.0001262369,0.001453533,0.02327708,0.9731253,0.00007361909,0.00003013514,0.0001540296,0.00009718564,0.0001371553,0.001160962,0.00001877073],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002973452,0.9952568,0.0005311823,0.0001838637,0.0001263249,0.0003428261,0.0003696487,0.00002227932,0.0001935385],"genre_scores_gemma":[0.09302704,0.9012659,0.002397793,0.0007481513,0.0002545823,0.001297831,0.0006997653,0.00002898326,0.0002799858],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02226855,"threshold_uncertainty_score":0.08183825,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}